Insights

Clinical momentum RenovoRx is advancing a targeted oncology platform (TAMP) with recent enrollment in a borderline resectable pancreatic cancer setting and proactive clinical updates, signaling ongoing clinical momentum that presents cross-sell opportunities for companion diagnostics, services, and potential device-adjacent therapies.

Financial visibility Public disclosures of quarterly results and a quantifiable revenue range indicate a trackable financial profile suitable for outreach to potential partners or investors interested in strategic collaborations, licensing, or co-development agreements.

Technology stack A diverse tech stack including cloud infrastructure (AWS), data management (PostgreSQL, SAP, Sage Intacct), analytics (MATLAB), and identity management (Microsoft 365/AD) points to readiness for data-intensive collaborations, analytics services, and digital health integrations.

Market positioning Focus on FDA-cleared drug-delivery devices and targeted oncology therapies positions RenovoRx as a gateway for collaborations in precision medicine, regional partnerships, and clinical trial support services with health systems and biotech developers.

News-driven engagement Consistent media coverage of presentations, peer-reviewed publications, and investor conferences provides multiple touchpoints for outreach around sponsorships, joint events, and opportunities to sponsor or participate in forums and studies.

Similar companies to Renovo

Renovo Tech Stack

Renovo uses 8 technology products and services including Sage Intacct, MATLAB, Linkedin Insight Tag, and more. Explore Renovo's tech stack below.

Media & News

Renovo's Email Address Formats

Renovo uses at least 3 email formats:
Renovo Email FormatsExamplePercentage
First.Last@renovo.comJohn.Doe@renovo.com
100%
FLast@renovo1.comJDoe@renovo1.com
99%
Last@renovo1.comDoe@renovo1.com
1%

Frequently Asked Questions

What is Renovo's stock symbol?

Minus sign iconPlus sign icon
Renovo is a publicly traded company; the company's stock symbol is RNXT.

What is Renovo's official website and social media links?

Minus sign iconPlus sign icon
Renovo's official website is renovo1.com and has social profiles on LinkedIn.

How much revenue does Renovo generate?

Minus sign iconPlus sign icon
As of October 2026, Renovo's annual revenue is estimated to be $25M - $50M.

What is Renovo's SIC code and NAICS code?

Minus sign iconPlus sign icon
Renovo's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Renovo have currently?

Minus sign iconPlus sign icon
As of October 2026, Renovo has approximately 120 employees across 6 continents, including Europe, North America and South America. Key team members include Senior Vice President Development: J. H., Senior Vice President Discovery: N. O. and Operations Director: M. J. Explore Renovo's employee directory with LeadIQ.

What industry does Renovo belong to?

Minus sign iconPlus sign icon
Renovo operates in the Biotechnology Research industry.

What technology does Renovo use?

Minus sign iconPlus sign icon
Renovo's tech stack includes Sage Intacct, MATLAB, Linkedin Insight Tag, Amazon Web Services, SAP, PostgreSQL, Microsoft 365 and Microsoft Active Directory.

What is Renovo's email format?

Minus sign iconPlus sign icon
Renovo's email format typically follows the pattern of First.Last@renovo.com. Find more Renovo email formats with LeadIQ.
Renovo logo

Renovo

Biotechnology ResearchUnited Kingdom51-200 Employees

Renovo is a mid-sized biotechnology research company based in the United Kingdom. It concentrates on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device. The firm aims to improve cancer treatment by enabling localized delivery of chemotherapeutics to tumors, potentially increasing local potency while reducing systemic exposure. Its activities include platforms and approaches designed to support intra-arterial delivery of cancer drugs.

The primary customers are oncology clinicians and healthcare organizations seeking more precise, localized cancer therapies. In 2026, the company announced that oxaliplatin received FDA orphan-drug designation for the treatment of pancreatic cancer, marking a regulatory milestone for its pipeline.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
RNXT
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $25M - $50M

    Renovo's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.